Global Mpox Trends Report | by WHO (published: October 2025)
This report provides an overview of the mpox1 epidemiological situation, based on global surveillance data reported to WHO since 01 January 2022. This surveillance was initiated in response to the unprecedented human-to-human transmission of monkeypox virus (MPXV) that occurred globally in 2022, leading to the first Public Health Emergency of International Concern (PHEIC) for mpox. Following the lifting of that PHEIC, surveillance updates were issued monthly for all WHO regions. With the declaration of the second PHEIC in August 2024, surveillance was further strengthened in most African countries, where updates are now provided on a weekly basis. The mpox second PHEIC was lifted on 05 September 2025.
This open knowledge-sharing community is in place to support research teams and encourage local research to address the pressing gaps in mpox evidence. New data is needed to understand transmission, severity of disease, and longevity, to support vaccine development and testing, better detection, and diagnosis. Social science also strongly needs to support public health education, awareness, and detection to improve access to care and slow transmission.
In this area, you will find the latest updates/resources to support your research from across the network, as well as trusted sources of further information from WHO and other organisations. Please check back here regularly as more resources and tools are added.
Interim guidance on social and behavioural research for the mpox public health response - March 2025
This interim guidance aims to clarify standards for high-quality, ethical, social and behavioural research to strengthen the public health response to the ongoing mpox PHEIC for community protection. The guidance is particularly relevant to rapid research that aims to inform near real-time decision-making and action, but is equally applicable to longer-term research that may be critical for informing future outbreak preparedness and response.
This testing strategy for mpox is a guide for stakeholders supporting the mpox response, including Ministries of Health and other Government agencies, national mpox response task-forces, funding and implementing agencies, public health experts, epidemiologists, front-line healthcare service providers, including clinicians, nurses, laboratory professionals, community healthcare workers and others involved in outbreak preparedness and response activities for enhanced community protection.
Current data regarding mpox clade Ib and clade IIb cases within the United Kingdom. Earlier reports spanning the period from June 2022 through January 2025 contain details exclusively on clade IIb cases.
WHO Director-General Dr Tedros Adhanom Ghebreyesus has determined that the upsurge of mpox in the Democratic Republic of the Congo (DRC) and a growing number of countries in Africa constitutes a public health emergency of international concern (PHEIC) under the International Health Regulations (2005) (IHR).
The new mpox strain spreading from the Democratic Republic of Congo (DRC) is mutating faster than expected, particularly in regions lacking the resources for proper tracking, scientists report. This has led to "numerous unknowns" about the virus’s severity and transmission, complicating the global response, experts in Africa, Europe and the United States told Reuters.
Just a little over a year since declaring that Covid-19 was no longer a public health emergency of international concern and that the 2022-23 mpox crisis had subsided, the World Health Organization finds itself warning of another crisis as cases of yet another new strain of the mpox virus spread from the Democratic Republic of the Congo to other countries in Africa and beyond.
WHO has asked manufacturers of mpox in vitro diagnostics (IVDs) to submit an expression of interest for Emergency Use Listing (EUL). WHO has been in ongoing discussions with manufacturers about the need for effective diagnostics, particularly in low-income settings. The request for EUL expressions of interest by manufacturers is the latest development in these discussions.
Interim Guidance: Infection Prevention and Control for the Management of Mpox in People in Situations of Vulnerability such as Prisons and Other Custodial Facilities. 1 December 2022
VIII Ad Hoc Meeting of the PAHO Technical Advisory Group (TAG) on Vaccine Preventable Diseases. Technical report on the monkeypox outbreak in several countries, May 31, 2022 (virtual)
IX Ad Hoc Meeting of the Technical Advisory Group (GTA) IX Ad Hoc Meeting of the PAHO Technical Advisory Group (TAG) on Vaccine Preventable Diseases, July 25, 2022 (virtual)
IX Ad Hoc Meeting of the Technical Advisory Group (GTA) IX Ad Hoc Meeting of the PAHO Technical Advisory Group (TAG) on Vaccine Preventable Diseases, July 25, 2022 (virtual)
